Shares in drug delivery company Nektar Therapeutics fell through
the floor yesterday after it was suggested that regulators in
Europe were not prepared to approve an inhaled insulin product for
diabetes based on its technology.
Fisher Scientific, the US-based science and laboratory products
group, hinted earlier this week that it may be looking to make
another acquisition, despite its prediction of a period of
consolidation in the wake of its $714 million...
Although there are some signs of an economic recovery that should
help its business, the European chemical and pharmaceutical
industry can expect to have another difficult year in 2004.
Dutch pharmaceuticals, chemicals and coatings group Akzo Nobel has
reported a 23 per cent decline in third-quarter earnings, roughly
in line with expectations, on the back of continued pressure on its
pharmaceuticals division.
Recordati is expecting to sell off its pharmaceutical chemical
operations by the end of next year or early in 2004, according to
the company's chief executive, who expects €80-€90m in proceeds for
the sale.